Key result
This review summarizes pre-clinical and clinical trials of new-generation Resolute and Xience V drug-eluting stents, which were developed to address late stent thrombosis seen with earlier stents.
Answers are grounded in this paper and cite their sources.
This review summarizes the pre-clinical and clinical evidence for new-generation everolimus- and zotarolimus-eluting stents, which have replaced first-generation devices to mitigate late stent thrombosis risks.
Compared to bare metal stent angioplasty, first‐generation drug‐eluting stents (DES) have markedly reduced the incidence of in‐stent restenosis. However, given the increased concerns over late and very late stent thrombosis, newer‐generation DES were developed. To date, these DES have virtually replaced the use of first‐generation DES worldwide. In this review article, we carefully consider the pre‐clinical and clinical trials that have been performed with currently available, european conformity‐marked and Food and Drug Administration–approved new‐generation Resolute ® and Xience V ® DES . (J Interven Cardiol 2013;26:278–286)
No takes yet. Share an insight, caveat, or question.
Dyck et al. (2013) conducted a review in Coronary artery disease requiring stenting. New-generation drug-eluting stents (Resolute and Xience V) vs. First-generation drug-eluting stents and bare metal stents was evaluated. This review summarizes pre-clinical and clinical trials of new-generation Resolute and Xience V drug-eluting stents, which were developed to address late stent thrombosis seen with earlier stents.
Synapse has enriched 10 related papers. Consider them for comparative context: